152 related articles for article (PubMed ID: 36852868)
21. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer.
Venkatasubbarao K; Peterson L; Zhao S; Hill P; Cao L; Zhou Q; Nawrocki ST; Freeman JW
Mol Cancer; 2013 Sep; 12(1):104. PubMed ID: 24025152
[TBL] [Abstract][Full Text] [Related]
22. Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3.
Shou J; You L; Yao J; Xie J; Jing J; Jing Z; Jiang L; Sui X; Pan H; Han W
Cancer Lett; 2016 Aug; 379(1):124-33. PubMed ID: 27264264
[TBL] [Abstract][Full Text] [Related]
23. Verbascoside Inhibits Glioblastoma Cell Proliferation, Migration and Invasion While Promoting Apoptosis Through Upregulation of Protein Tyrosine Phosphatase SHP-1 and Inhibition of STAT3 Phosphorylation.
Jia WQ; Wang ZT; Zou MM; Lin JH; Li YH; Zhang L; Xu RX
Cell Physiol Biochem; 2018; 47(5):1871-1882. PubMed ID: 29961065
[TBL] [Abstract][Full Text] [Related]
24. 15-Lipoxygenase-1-enhanced Src-Janus kinase 2-signal transducer and activator of transcription 3 stimulation and monocyte chemoattractant protein-1 expression require redox-sensitive activation of epidermal growth factor receptor in vascular wall remodeling.
Singh NK; Wang D; Kundumani-Sridharan V; Van Quyen D; Niu J; Rao GN
J Biol Chem; 2011 Jun; 286(25):22478-88. PubMed ID: 21536676
[TBL] [Abstract][Full Text] [Related]
25. Lymecycline reverses acquired EGFR-TKI resistance in non-small-cell lung cancer by targeting GRB2.
Chen Y; Wu J; Yan H; Cheng Y; Wang Y; Yang Y; Deng M; Che X; Hou K; Qu X; Zou D; Liu Y; Zhang Y; Hu X
Pharmacol Res; 2020 Sep; 159():105007. PubMed ID: 32561477
[TBL] [Abstract][Full Text] [Related]
26. Kaempferol and Biomodified Kaempferol from
Dos Santos JS; Suzan AJ; Bonafé GA; Fernandes AMAP; Longato GB; Antônio MA; Carvalho PO; Ortega MM
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445894
[TBL] [Abstract][Full Text] [Related]
27. EGFR tyrosine kinase inhibition radiosensitizes and induces apoptosis in malignant glioma and childhood ependymoma xenografts.
Geoerger B; Gaspar N; Opolon P; Morizet J; Devanz P; Lecluse Y; Valent A; Lacroix L; Grill J; Vassal G
Int J Cancer; 2008 Jul; 123(1):209-16. PubMed ID: 18386816
[TBL] [Abstract][Full Text] [Related]
28. Treatment with cucurbitacin B alone and in combination with gefitinib induces cell cycle inhibition and apoptosis via EGFR and JAK/STAT pathway in human colorectal cancer cell lines.
Yar Saglam AS; Alp E; Elmazoglu Z; Menevse S
Hum Exp Toxicol; 2016 May; 35(5):526-43. PubMed ID: 26183715
[TBL] [Abstract][Full Text] [Related]
29. Secreted GRP78 activates EGFR-SRC-STAT3 signaling and confers the resistance to sorafeinib in HCC cells.
Li R; Yanjiao G; Wubin H; Yue W; Jianhua H; Huachuan Z; Rongjian S; Zhidong L
Oncotarget; 2017 Mar; 8(12):19354-19364. PubMed ID: 28423613
[TBL] [Abstract][Full Text] [Related]
30. Synergistic anti-tumor effect of combined inhibition of EGFR and JAK/STAT3 pathways in human ovarian cancer.
Wen W; Wu J; Liu L; Tian Y; Buettner R; Hsieh MY; Horne D; Dellinger TH; Han ES; Jove R; Yim JH
Mol Cancer; 2015 May; 14():100. PubMed ID: 25928246
[TBL] [Abstract][Full Text] [Related]
31. Enhanced sensitivity of pancreatic cancer cells to concurrent inhibition of aberrant signal transducer and activator of transcription 3 and epidermal growth factor receptor or Src.
Jaganathan S; Yue P; Turkson J
J Pharmacol Exp Ther; 2010 May; 333(2):373-81. PubMed ID: 20100905
[TBL] [Abstract][Full Text] [Related]
32. Licochalcone B inhibits growth and induces apoptosis of human non-small-cell lung cancer cells by dual targeting of EGFR and MET.
Oh HN; Lee MH; Kim E; Yoon G; Chae JI; Shim JH
Phytomedicine; 2019 Oct; 63():153014. PubMed ID: 31323446
[TBL] [Abstract][Full Text] [Related]
33. Antiglioma effects of N6-isopentenyladenosine, an endogenous isoprenoid end product, through the downregulation of epidermal growth factor receptor.
Ciaglia E; Abate M; Laezza C; Pisanti S; Vitale M; Seneca V; Torelli G; Franceschelli S; Catapano G; Gazzerro P; Bifulco M
Int J Cancer; 2017 Feb; 140(4):959-972. PubMed ID: 27813087
[TBL] [Abstract][Full Text] [Related]
34. Golgi phosphoprotein 3 sensitizes the tumour suppression effect of gefitinib on gliomas.
Wang X; Wang Z; Zhang Y; Wang Y; Zhang H; Xie S; Xie P; Yu R; Zhou X
Cell Prolif; 2019 Jul; 52(4):e12636. PubMed ID: 31094020
[TBL] [Abstract][Full Text] [Related]
35. Shikonin enhances sensitization of gefitinib against wild-type EGFR non-small cell lung cancer via inhibition PKM2/stat3/cyclinD1 signal pathway.
Tang JC; Ren YG; Zhao J; Long F; Chen JY; Jiang Z
Life Sci; 2018 Jul; 204():71-77. PubMed ID: 29738778
[TBL] [Abstract][Full Text] [Related]
36. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
37. Anlotinib combined with temozolomide suppresses glioblastoma growth via mediation of JAK2/STAT3 signaling pathway.
Xu P; Wang H; Pan H; Chen J; Deng C
Cancer Chemother Pharmacol; 2022 Feb; 89(2):183-196. PubMed ID: 34997858
[TBL] [Abstract][Full Text] [Related]
38. Antibody-based targeting of CD24 enhances antitumor effect of cetuximab via attenuating phosphorylation of Src/STAT3.
Chen Z; Wang T; Tu X; Xie W; He H; Wang M; Zhang J
Biomed Pharmacother; 2017 Jun; 90():427-436. PubMed ID: 28391164
[TBL] [Abstract][Full Text] [Related]
39. Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells.
Qin B; Ariyama H; Baba E; Tanaka R; Kusaba H; Harada M; Nakano S
Cancer Chemother Pharmacol; 2006 Nov; 58(5):577-84. PubMed ID: 16532343
[TBL] [Abstract][Full Text] [Related]
40. FoxO3a inhibiting expression of EPS8 to prevent progression of NSCLC: A new negative loop of EGFR signaling.
Wen Q; Jiao X; Kuang F; Hou B; Zhu Y; Guo W; Sun G; Ba Y; Yu D; Wang D; Zhang F; Qiao HC; Wang S; Tang S; Qiao H
EBioMedicine; 2019 Feb; 40():198-209. PubMed ID: 30738830
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
